 
 
Official Title:  Randomized Trial of Community Health Worker -led Decision Coaching 
to Promote Shared Decision Making for Prostate Cancer Screening 
Among Black Male Patients and Their Providers   
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  18-[ZIP_CODE]  
Document Type:   Study Protocol and Statistical Analysis Plan  
Date of the 
Document:  • October 16, 2020  
 
  Page i 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017   
   
RANDOMIZED TRIAL OF COMMUNITY HEALTH WORKER-LED 
DECISION COACHING TO  PROMOTE SHARED DECI SION MAKING 
FOR PROSTATE CANCER SCREENING AMONG BLACK MALE PATIENTS AND THEIR P ROVIDERS. 
 
 
 
Principal Investigator : 
 [INVESTIGATOR_513088] V. Makarov, MD, MHS  
Population Health 
[ADDRESS_664231], 6th Floor  
[LOCATION_001], NY  [ZIP_CODE]  
[EMAIL_9747] 
[PHONE_10654]  
Additional Investigators : 
 Joseph E. Ravenell, MD, MS  
Population Health 
[ADDRESS_664232], 6th Floor  
[LOCATION_001], NY  [ZIP_CODE]  
[EMAIL_9748] 
[PHONE_10655]  
NYULMC Study  Number:  i18-[ZIP_CODE]  
Funding Sponsor:   NIH 
9000 Rockville Pi[INVESTIGATOR_2531], Bethesda, Maryland [ZIP_CODE] 
[PHONE_10561]  
ClinicalTrials.gov 
Number                  
 
Initial version:  07/30/2018  
Amended: 10.01 .2020  
 
Study number:  i18-[ZIP_CODE]   Page ii 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017   
 
Statement of Compliance  
 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), any other applicable US government research regulations , and 
institutional research policies and procedures . The Principal Investigator [INVESTIGATOR_7433], 
or changes to the protocol will take place without prior agreement from the sponsor and documented 
approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate 
hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed Human Subjects Protection Training.  
  
Study number:  i18-[ZIP_CODE]   Page iii 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  Table of Contents  
 
PROTOCOL SUMMARY  .............................................................................................................................. 1 
1 KEY ROLES  ......................................................................................................................................... 3 
2 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIFIC  RATIONALE  ....................... 3 
2.1 BACKGROUND INFORMATION AND RELEVANT LITERATURE  ................................................................ 3 
2.2 RATIONALE  .................................................................................................................................... 3 
2.3 POTENTIAL RISKS & BENEFITS  ........................................................................................................ 4 
2.3.1  Known Potential Risks  ............................................................................................................. 4 
2.3.2  Known Potential Benefits  ........................................................................................................ 4 
3 OBJECTIVES AND PURPO SE ........................................................................................................... 4 
3.1 PRIMARY OBJECTIVE  ...................................................................................................................... 4 
3.2          SECONDARY OBJECTIVES  (IF APPLICABLE)  .................................................................................... 4 
4 STUDY DESIGN AND ENDPOINTS .................................................................................................... 5 
4.1 DESCRIPTION OF STUDY DESIGN  .................................................................................................... 5 
4.2 STUDY ENDPOINTS ......................................................................................................................... 5 
4.2.1  Primary Study Endpoints  ......................................................................................................... 5 
4.2.2  Secondary Study Endpoints  .................................................................................................... 5 
4.2.3  Exploratory Endpoints  ............................................................................................................. 6 
5 STUDY ENROLLMENT AND WITHDRAWAL  .................................................................................... 6 
5.1 INCLUSION CRITERIA  ...................................................................................................................... 6 
5.2 EXCLUSION CRITERIA  ..................................................................................................................... 6 
5.3 VULNERABLE SUBJECTS  ................................................................................................................. 6 
5.4 STRATEGIES FOR RECRUITMENT AND RETENTION  ............................................................................ 6 
5.4.1  Use of DataCore/Epic Information for Recruitment Purposes  ................................................ 8 
5.5 DURATION OF STUDY PARTICIPATION  .............................................................................................. 8 
5.6 TOTAL NUMBER OF PARTICIPANTS AND SITES .................................................................................. 8 
5.7 PARTICIPANT WITHDRAWAL OR TERMINATION  .................................................................................. 8 
5.7.1  Reasons for Withdrawal or Termination  .................................................................................. 8 
5.7.2  Handling of Participant Withdrawals or Termination  ............................................................... 9 
5.7.3  Premature Termination or Suspension of Study  ..................................................................... 9 
6 BEHAVIORAL/SOCIAL IN TERVENTION  ........................................................................................... 9 
6.1 STUDY BEHAVIORAL INTERVENTION (S) DESCRIPTION  ....................................................................... [ADDRESS_664233] Compliance with Study Intervention  ................................................ 11 
7 STUDY PROCEDURES AND SCHEDULE  ....................................................................................... 11 
7.1 STUDY PROCEDURES /EVALUATIONS  ............................................................................................. [ADDRESS_664234] of Care Study Procedures  ..................................................................................... 13 
7.2 STUDY SCHEDULE  ........................................................................................................................ 13 
7.2.1  Screening  .............................................................................................................................. 13 
7.2.2  Enrollment  ............................................................................................................................. 13 
7.2.3  Intermediate Visits  ................................................................................................................. 13 
7.2.4  Final Study Visit  ..................................................................................................................... 14 
7.2.5  Withdrawal Visit  ..................................................................................................................... 14 
7.2.6  Unscheduled Visit  .................................................................................................................. 14 
7.3 CONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES  .................................................... 14 
7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES  ................................................................................ 14 
Study number:  i18-[ZIP_CODE]   Page iv 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  7.4.1  Precautionary Medications, Treatments, and Procedures  .................................................... 14 
7.5 PROHIBITED MEDICATIONS , TREATMENTS , AND PROCEDURES  ........................................................ 14 
7.6 PARTICIPANT ACCESS TO STUDY INTERVENTION AT STUDY CLOSURE  ............................................. 14 
8 ASSESSMENT OF SAFETY  ............................................................................................................. 14 
8.1 SPECIFICATION OF SAFETY PARAMETERS  ...................................................................................... 14 
8.1.1  Definition of Adverse Events (AE)  ......................................................................................... 15 
8.1.2  Definition of Serious Adverse Events (SAE)  ......................................................................... 15 
8.1.3  Definition of Unanticipated Problems (UP)  ............................................................................ 15 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  ....................................................................................... 16 
8.2.1  Severity of Event  ................................................................................................................... 16 
8.2.2  Relationship to Study Intervention ......................................................................................... 16 
8.2.3  Expectedness  ........................................................................................................................ 17 
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP .................................... 17 
8.4 REPORTING PROCEDURES – NOTIFYING THE IRB .......................................................................... 17 
8.4.1  Adverse Event Reporting  ...................................................................................................... 17 
8.4.2  Serious Adverse Event Reporting  ......................................................................................... 17 
8.4.3  Unanticipated Problem Reporting  ......................................................................................... 18 
8.5 REPORTING PROCEDURES – NOTIFYING THE STUDY SPONSOR  ...................................................... 18 
8.6 STUDY HALTI NG RULES ................................................................................................................ 18 
8.7 SAFETY OVERSIGHT  ..................................................................................................................... 19 
9 CLINICAL MONITORING  .................................................................................................................. 19 
10 STATISTICAL CONSIDER ATIONS  .................................................................................................. 19 
10.1  STATISTICAL AND ANALYTICAL PLANS  ........................................................................................... 19 
10.2         PATIENT SURVEY OUTCOME VARIABLES ………………………………………………………………. 20 
10.3  STATISTICAL HYPOTHESES  ........................................................................................................... 20 
10.4  ANALYSIS DATASETS  .................................................................................................................... 22 
10.5  DESCRIPTION OF STATISTICAL METHODS  ...................................................................................... 22 
10.5.1  General Approach  ............................................................................................................. 22 
10.5.2  Analysis of the Primary Efficacy Endpoint(s)  .................................................................... 22 
10.5.3  Analysis of the Secondary Endpoint(s)  ............................................................................. 23 
10.5.4  Safety Analyses  ................................................................................................................ 23 
10.5.5  Adherence and Retention Analyses  .................................................................................. 23 
10.5.6  Baseline Descriptive Statistics  .......................................................................................... 23 
10.5.7  Planned Interim Analysis  .................................................................................................. 23 
10.5.8  Additional Sub- Group Analyses  ........................................................................................ 23 
10.5.9  Multiple Comparison/Multiplicity  ........................................................................................ 24 
10.5.10  Tabulation of Individual Response Data  ........................................................................... 24 
10.5.11  Exploratory Analyses  ........................................................................................................ 24 
10.6  SAMPLE SIZE ............................................................................................................................... 25 
10.7  MEASURES TO MINIMIZE BIAS ....................................................................................................... 25 
10.7.1  Enrollment/Randomization/Masking Procedures  .............................................................. 25 
10.7.2  Evaluation of Success of Blinding  ..................................................................................... 25 
10.7.3  Breaking the Study Blind/Participant Code  ....................................................................... 25 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DA TA/DOCUMENTS  ................................. 25 
12 QUALITY ASSURANCE AN D QUALITY CONTROL  ....................................................................... 26 
13 ETHICS/PROTECTION OF  HUMAN SUBJECTS  ............................................................................. [ADDRESS_664235]  ..................................................................................................... 26 
13.3  INFORMED CONSENT PROCESS . ................................................................................................... 27 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  ............... 27 
13.3.2  Consent Procedures and Documentation  ......................................................................... 27 
13.4  PARTICIPANT AND DATA CONFIDENTIALITY  .................................................................................... 29 
Study number:  i18-[ZIP_CODE]   Page v 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664236]  POLICY  .................................................................................................. 32 
18 REFERENCES  ................................................................................................................................... 34 
19 ATTACHMENTS  ................................................................................................................................ 35 
 
  
  
Study number:  i18-[ZIP_CODE]   Page vi 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664237] of Abbreviations  
 
 
AE Adverse Event/Adverse Experience  
CFR Code of Federal Regulations  
CHW  Community Health Worker  
CRF Case Report Form  
CSOC  Clinical Study Oversight Committee  
DCC  Data Coordinating Center  
DHHS  Department of Health and Human Services  
DSMB  Data and Safety Monitoring Board  
FQHC  Federally Qualified Health Center  
FFR Federal Financial Report  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
ICF Informed Consent Form  
IRB Institutional Review Board  
ISM Independent Safety Monitor  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_33891])  
NIH National Institutes of Health  
OHRP  Office for Human Research Protections  
OHSR  Office of Human Subjects Research  
PI [INVESTIGATOR_513089]/Serious Adverse Experience  
SDM  Shared Decision -Making  
SOP  Standard Operating Procedure  
US [LOCATION_002]  
 
 
 
    
Study number:  i18-[ZIP_CODE]                                                                               page 1 
 Version: 1 0.01.20  
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_248710]/Device Template Version: [ADDRESS_664238] common non- cutaneous malignancy among men in the U.S.  
The USPSTF encourages prostate- specific antigen (PSA) testing 
decisions to be based on shared decision- making, clinician 
professional judgment, and patient preferences. The purpose of this study is to evaluate the efficacy of a Community Health Worker -led 
decision -coaching program to facilitate SDM and PSA screening 
among Black men concerning decision quality, the decision- making 
process, patient -provider communication and PSA utilization for Black 
men in the primary care setting. A randomized trial assessing the effect of community health worker decision coaching sessions on the quality of decision- making in PSA screening for Black men aged 40-
69. The study aims to enroll around 228 patients and 7 providers.  
Patients will spend 6- 9 months participating in the intervention; 
providers will spend approximately 4 years participating in the intervention.  
 
Intervention  Behavioral  
Objectives  Our study primarily aims to assess 1) the effectiveness of a CHW as 
decision coach to improve decisions among Black men considering 
PSA screening, and 2) whether CHW decision coaching will improve 
providers’ experience with PSA counseling  to test whether a CHW -led 
decision coaching program affects decision quality, the decision 
making process, patient -provider communication and PSA utilization 
for Black men in the primary care setting.  
Methodology  Randomized trial  
Study Endpoints/Outcomes  Primary outcomes: decision quality, knowledge, and PSA screening 
rates   
Study Duration  5 years  
Participant Duration  Patients: 6-9 months; Providers: 3- 4 years  
Duration of behavioral 
intervention  ~3-4 years , until target patient enrollment is reached  
Population  Black men 40 -69 years old visiting the Federally Qualified Health 
Center (FQHC) study site  for primary care visit; providers that treat 
patient subjects.  
Study Sites  Flatbush Family Health Center at NYU Langone, part of NYU 
Lutheran Family Health Center (FHC) network  
Number of participants  Approximately 228 patients, up to 15 providers, 2 administrative staff  
Study number:  i18-[ZIP_CODE]   Page 2 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  Description of Study 
Intervention/Procedure  Patients will be randomized to receive 1) a decision aid along with 
decision coaching on PSA screening from a CHW or 2) a decision aid along with CHW interaction on dietary and lifestyle modification to 
serve as an attention control.  The intervention group will receive an 
educational counseling session from an extensively - trained CHW  
Coach to facilitate the decision making process in a 1:1 setting for 
potential PSA screening. The Coach will offer patients in the control 
arm general health coaching using an educational tool focused on 
dietary and lifestyle modification to reduce the risk of cardiovascular 
disea se. 
Key Procedures  Patients: 4 surveys, decision coaching (behavioral intervention) or 
attention (health discussion, control), subset sample for 1 interview  
Providers: 2 one- time surveys, 1 survey after each appointment with 
enrolled pa tient, 1 interview  
Statistical Analysis  We will use linear mixed models (for continuous outcomes), logistic 
generalized linear mixed models (for binary outcomes), and random effects multinomial models (for outcomes with more than 2 levels, 
such as adherence). In  all  models,  time  (2  dummy  variables)  and  
intervention  will  be  included  as  fixed  effect; provider will be a random effect. The intervention effect of interest is the treatment X 
time interaction.  
  
 
  
Study number:  i18-[ZIP_CODE]   Page 3 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664239], [LOCATION_001], NY [ZIP_CODE]  
[PHONE_10654]  
[EMAIL_9747]  
 
Joseph Ravenell, MD, MS, Associate Professor of Population Health  
[LOCATION_001] University School of Medicine  
[ADDRESS_664240], [LOCATION_001], NY [ZIP_CODE]  
[PHONE_10655]  
[EMAIL_9748]   
 Program Officer  
Andrew Louden, Ph.D., Program Officer  
NIMHD Clinical and Health Services Research Branch  
[ADDRESS_664241], Bethesda, MD  [ZIP_CODE]  
[PHONE_10656]  
[EMAIL_9749]   
 
Study Contact  
[CONTACT_513095], MHS  
[LOCATION_001] University School of Medicine  
[ADDRESS_664242] #617E, [LOCATION_001], NY [ZIP_CODE]  
[PHONE_10657]  
  
[ADDRESS_664243] common non- cutaneous malignancy among men in the [LOCATION_002] and 
affects Black men disproportionately. Experts agree prostate- specific antigen (PSA) –based prostate 
cancer screening is a preference- sensitive decision and recommend Shared Decision Making (SDM), an 
approach where clinicians and patients discuss the best evidence and patients are supported to achieve informed decisions.  
 The US Preventative Services Task Force (USPSTF) recently proposed a revision of their Prostat e 
Cancer Screening Statement, now encouraging that screening decisions happen within a SDM framework based on professional judgment and patient preference. USPSTF has also recognized SDM is underutilized in practice, especially among Black men, and has emphasized the need for research to 
understand how best to implement and adapt SDM programs within diverse populations. We seek to 
optimize, evaluate and disseminate a program to help Black men understand their increased risk of prostate cancer and receive guidance sensitive to their values and preferences when deciding about PSA screening.  Our intervention is entitled: Randomized trial of community health worker -led decision 
coaching to promote shared decision making for prostate cancer screening among Black  male patients 
and their providers . 
 
2.[ADDRESS_664244] available evidence, the [LOCATION_002] Preventive Services Task Force (USPSTF) recently recommended “that clinicians inform men ages 55 to 69 years about the potential benefits and 
Study number:  i18-[ZIP_CODE]   Page 4 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  harms of pr ostate- specific antigen (PSA) –based screening for prostate cancer.”[ADDRESS_664245] a 
mortality benefit to screening Black men earlier than age 55. As a result, the Task Force proposed clinicians 
inform Black men “about their increased risk of developi[INVESTIGATOR_513090], personal decision about whether 
to be screened.”
1 USPSTF now reco mmends an informed decision making approach to PSA screening for 
Black men that necessarily involves the clinician in the process, i.e. a “shared decision making” approach.  
Few studies have explored decision coaching in PSA screening. Myers et al
[ADDRESS_664246] of a decision coaching among Black m en. However, the study endpoint was PSA screening 
rate, not the decision process.  
 
In summary: SDM is un derutilized in PSA screening;  there is a local need for a balanced discussion about 
screening among Black men in primary care practices in [LOCATION_001] City , and a CHW -led decision coaching 
intervention is feasible, and potentially as effective as a physician- led discussion for increasing prostate 
cancer knowledge and decreasing decisional conflict.  
2.3 Potential Risks & Benefits 
2.3.[ADDRESS_664247] to ensure information security.  
2.3.2  Known Potential Benefits 
The proposed study may directly benefit the participants because the intervention provides resources to patients that will help them to make an informed, value -concordant decision regarding PSA -screening for 
prostate cancer.  The intervention group will receive an educational counseling session from an 
extensively - trained CHW to facilitate the decision making process in a 1:[ADDRESS_664248] benefits through extrapolation 
of the intervention beyond this site to other community settings and populations . 
3 Objectives and Purpose  
3.1 Primary Objective  
Aim 1 : To test whether a CHW -led decision coaching program affects decision quality, the decision making 
process, patient -provider communication and PSA utilization for Black men in the primary care setting.   
Secondary Objectives (if applicable)  
Aim 2:  Test whether a CHW -led decision coaching program improves provider experience with 
counseling Black men considering PSA screening  
Aim 3:  To determine the cost and cost impact of a CHW -led decision coaching program for PSA 
screening.  
Study number:  i18-[ZIP_CODE]   Page 5 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  Aim 4:  To assess participant behaviors and norms around PSA screening and assess perceptions of the 
feasibility, acceptability and sustainability of CHW -led decision coaching in the primary care setting. 
 
4 Study Design and Endpoints/Outcomes  
4.1 Description of Study Design  
We propose a CHW -led decision- coaching program to facilitate SDM for prostate cancer screening 
discussions in Black men at a primary care FQHC. This study will enroll  Black men who are patients at 
the participating clinical site (aged 40- 69 years) and the providers who care for them (up to 15). Patients 
will be randomized to receive 1) a decision aid along with decision coaching on PSA screening from a 
CHW or 2) a decision aid along with CHW interaction on dietary and lifestyle modification to serve as an attention control. The independent randomization process will be implemented within each provider and 
we will control for age by [CONTACT_513096]: 40-54 years and 55- 69 years. All study staff and 
providers will be blinded to the randomization groups. Conservatively assuming a 20% drop out, we will 
recruit 228 participants (114/group) to achieve a final sample of 182 (91/group) patients. This sample size  
will allow us to be sufficiently powered to detect differences in our primary study outcomes: knowledge, indicative of decision quality, and differences in PSA screening rates.  
Among providers, we will assess perceptions of intervention acceptability and feasibility. We will explore 
communication in both groups. We will also conduct a cost analysis to measure program cost. Our results will enhance understanding of the efficacy, cost -effectiveness, and sustainability of CHW intervention in a 
community clin ic setting. Findings will inform the subsequent design of a scalable intervention to promote 
adoption and integration of SDM across contexts and empower high- risk, vulnerable populations.  
 
Due to the COVID19 crisis, we will be conducting the study both remotely and in person at the study site 
following the safety measures of social distancing, open spaces, and wearing PPE at all times 
implemented at the FQHC by [CONTACT_513097]. Participants who are scheduled for in- office 
appointments who are interested in participating in our study in- person will be contact[CONTACT_513098]. Participants who prefer to participate in our study through a WebEx video conference or a phone call will be consented to as preferred via a HIPAA -
compliant platform, REDCap. Only essential research personnel like our Community Health Workers who are needed for in- person research interactions will be attending the F QHC when scheduled for patient 
intervention. Our CHWs will undergo NP swab for SARS- CoV-[ADDRESS_664249] screen at facility entrances.  CHWs will maintain 6 feet of  separation when 
possible in waiting rooms or public areas within the site.  
 
4.2 Study Endpoints/Outcomes  
4.2.1  Primary Study Outcomes 
The following are primary study outcomes:  
• Decision quality: Measure of informed choice to evaluate screening decision and attitudes 
towards the screening test  
• Patient knowledge: Patient knowledge of prostate cancer and PSA screening  
• PSA screening rates: PSA rates collected through patient self -reported PSA testing and EHR 
data on PSA test utilization  
4.2.2  Secondary Study Outcomes  
Secondary study outcomes are:  
Study number:  i18-[ZIP_CODE]   Page 6 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  • Perception of quality of care: Patient perception of quality of care assessed through domains of 
communication, decisional self -efficacy, self -efficacy in communicating with their provider, 
satisfaction and decisional  conflict  
• Experience with decision coaching program: Provider experience with decision coaching program measured through encounter satisfaction, difficulty, and communication  
4.2.3  Exploratory Outcomes  
• Net cost of CHW -led decision coaching program for PSA screening: cost of CHW -led decision 
coaching program and its effect on prostate cancer screening costs by [CONTACT_513099]  
• Behaviors and norms around PSA screening and perceptions of feasibility and acceptability  of 
CHW  led decision coaching : Qualitative evaluation of patient and provider perceptions through in-
depth, semi -structured interviews and other qualitative data; triangulation of mixed methods data 
sets from patients and provider interviews, clinical encounters, and surveys to better understand implementation.  
[ADDRESS_664250] meet all of the following criteria:  
Patients:  
1. Age 40- 69 years old 
2. Black  
3. Male 
4. Attending FQHC for routine primary care appointment  
 
Providers:  
1. Provider at Flatbush Family Health Center  Federally Qualified Health Center (FQHC)  
2. Caring for patients that fit inclusion criteria  
5.2 Exclusion Criteria  
 
An individual who meets any of the following criteria will be excluded from participation in this study:  
Patients:  
1. Patients seen within 9 months  of other PSA tests  
2. Patients seen within 180 days after primary diagnosis of urinary obstruction, prostatitis, hematuria, other disorder of prostate, unexplained weight loss, or  lumbar  back pain 
3. Patients with a prior diagnosis of prostate cancer (ICD -10-CM C61)  
4. Patients visiting their provider for any indication other than a well -visit appointment  
Providers:  
1. Providers who do not treat adult male patients (e.g. OB/Gyns, pediatricians)  
5.3 Vulnerable Subjects  
N/A 
5.[ADDRESS_664251] 
information. A flyer will be distributed to eligible patients at the participating clinic. Study staff will also call patients by [CONTACT_18623]/or meet in- person at the clinic to confirm enrollment criteria, and if eligible, 
Study number:  i18-[ZIP_CODE]   Page 7 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664252] clinical care, and responses will be de- identified and reported as aggregate. If agreeable, the 
patient will be enrolled in the study and asked to come to the clinic one hour prior to his scheduled 
appointment. In light of the COVID19 pandemic, the patient may meet with the CHW remotely, if preferred, using a HIPAA compliant method. The CHW will also review consent materials with the patients prior to commencing study activities and data collection. Upon enrollment, the patient will be randomized 
to the CHW intervention or the control arm of the study. Men in the intervention group will be mailed 
and/or SendSafe Secure emailed a copy of the prostate cancer decision aid to review prior to their office visit, and men in the control group will be mailed an educational tool focused on dietary and lifestyle modification, unrelated to prostate cancer. Men randomized to either group will receive an additional copy of study information and consent materials. If a study staff member is unable to reach the patient by [CONTACT_648], further attempts to call the patients may continue once per week for up to three weeks. Following 
three unsuccessful phone call attempts per appointment, recruitment efforts will cease. Recruitment 
efforts  will be ongoing until the team has successfully recruited sufficient patients into the two study arms.   
  All eligible providers at Flatbush Family Health Center will be recruited with lists obtained from administrative leadership. Clinical and administrative leaders have already committed for the clinic to participate in the study. Providers will be recruited to participate in all components of the study at time of 
enrollment, including participation in the coaching program, surveys, and interviews. The Research 
Coordinators will notify eligible providers by [CONTACT_513100]. Providers will have the opportunity to respond to express interest in the study or to follow -up with further questions by [CONTACT_14223] 
e-mail. The Research Coordinators may also reach out to eligible providers by [CONTACT_648], e- mail, or in -person 
to discuss the study further following the primary e- mail. During these exchanges, the study team may set 
up a brief meeting to review details related to informed consent. These meetings will occur in private offices to ensure confidentiality. Study staff will remind providers that participation is voluntary and all responses and study outcomes will be de- identified, reported as aggregate and identifying data or 
responses will not be shared with institutional leadership. Following three e- mails and three unsuccessful 
phone call attempts, recruitment efforts will cease.   
  
We estimate that we will be able to meet recruitment goals of [ADDRESS_664253] yielded us long- term 
success including:   
1. We will reimburse both patient and provider participants for their time participating in the program and 
completing follow -up assessments. Clinician incentives are intended to compensate for the supplemental 
time that providers devote to each intervention participant appointment that is lost from regular clinical 
time. This will encourage providers to participate thoroughly in all elements of the intervention. The incentive will be $75 per individual patient participant seen during clinical appointments. Patients will receive payment of up to $ [ADDRESS_664254] information found in EHR is up to date and will confirm preferences for methods of follow -up.   
3. Participating providers will be engaged throughout the study and engaged with the investigator team through the Local Clinical Champi[INVESTIGATOR_5458]. Providers will receive encouragement from clinical and administrative leadership to continue participation in the study. The overarching goal of the study, to 
optimize clinical care for Black men within the community, will be reinforced during clinic staff meetings.  
4. Study staff will call or email participants to schedule follow -up assessments (surveys and interviews) 
Study number:  i18-[ZIP_CODE]   Page 8 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664255] attempts for participants who do not complete scheduled.  
 
5.4.1  Use of DataCore/Epic Information for R ecruitment Purposes  
 
This study will utilize EPIC to identify subjects. DataCore will request a report of eligible patients for 
research coordinator review. The data will be used to identify subjects and for contact [CONTACT_3031] (phone 
numbers).  The research coordinators will have access to Epic search results. Research coordi nators will 
use Epic to verify gender, age (DOB), race, dates of prior PSA tests and record results, dates of prior malignancies, and confirmation of no prostate cancer diagnosis. The search will encompass Black male patients with an upcoming primary care appointment at Flatbush Family Health Center who do not have a 
prostate cancer diagnosis and are between 40- [ADDRESS_664256] been complete for an enrolled patient or if a patient refuses enrollment. The 
coordinators will search Epic once for recruitment purposes, then again following the clinical appointment (post 6 months) to determine if a PSA test was done during the encounter results will be collected for analysis, up to [ADDRESS_664257] been identified, the study team will notify the treating physician (TP) that 
they have patients eligible to participate by [CONTACT_513101]: TP has been notified that the study team will 
contact [CONTACT_93578], by [CONTACT_31711], phone, email, or the MyChart portal etc.  Patients will be 
contact[CONTACT_513102]- person at the clinic. Any recruitment information sent by [CONTACT_341441].  
 Once contact [CONTACT_58661], approved recruitment language will be used to communicate the reason they are 
being contact[CONTACT_118674]. 
Should the potential subjects agree, the study team will provide the subjects with information regarding the next steps for participation.  
 If a subject requests information regarding opting out of further recruitment for all research, subjects will be directed to contact [CONTACT_79161]- contact -[EMAIL_2365] or 1- [PHONE_2698].  
5.5 Duration of Study Participation  
Enrolled patients will be participating in the study for approximately 6 months. Providers will participate for 
about 3- 4 years, until target enrollment of patients is reached and all follow -up assessments are 
complete. The study will run for about 5 total ye ars.  
5.6 Total Number of Participants and Sites  
We aim to enroll 228 participants (Black men eligible for PSA screening) and 5 (up to 15) providers, [ADDRESS_664258]. An investigator 
may terminate participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant  
• The participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation. 
Study number:  i18-[ZIP_CODE]   Page 9 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664259] their future interactions with their healthcare providers or employment at the FQHC.  
 
The clinical providers will be conducting any clinical evaluations that occur during the study visit and will 
administer usual care.  The PIs and Co- Investigators will meet biannually to review adverse event reports, 
participant complaints, and dropout rates . 
5.7.3  Premature Termination or Suspension of Study 
 This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. The suspending or terminating party will provide written notification, documenting the reason for study suspension or termination, to Danil V. Makarov, Joseph E. Ravenell, and the National Institutes of Health. If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_77941](s) for the termination or suspension.  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
• Determination of futility  
 Study may resume once concerns about safety, protocol compliance, data quality are addressed and satisfy the sponsor and/or IRB.  
 
6 Behavioral Intervention 
6.1 Study Behavioral Intervention(s) Description  
 
Decision coaches provide non- directive support to help patients consider options, prepare for provider 
discussion s, and implement their decisions. The decision coaching intervention will include the following 
components: 1) a structured interview with the patient that focuses on determining his understanding of 
his prostate cancer risk, his screening options, and his  goals and values related to their decision making, 
2) role playing exercises to improve shared decision making skills, and 3) the coach accompanying the patient to his appointment and taking notes.  
 
Intervention Arm: At the office visit, patients in the intervention arm will review the content of the mailed 
and/or emailed decision aid, including the values clarification exercise, with the Decision Coach. The Coach will then conduct a structured decision counseling session about prostate cancer screening. Decision coaching will include the following components: 1) a structured interview with the patient that 
focuses on determining his understanding of his prostate cancer risk, his screening options, and his goals 
and values related to their decision making, 2) role playing exercises to improve shared decision making 
skills, and 3) the Coach accompanying the patient to his appointment and taking notes.  
 T
he coaching session will begin by [CONTACT_513103]. The 
Coach wi ll ask the patient what questions he has and what information he needs to make his decision. 
The Coach will ascertain knowledge and ask the patient to think through the questions he would like to 
ask his provider.  
 
Finally, the Coach will talk to the patient about any concerns. The patient will have the opportunity to participate in role- playing exercises, allowing him to practice talking with his provider about treatment 
Study number:  i18-[ZIP_CODE]   Page 10 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664260] and revise the 
questionnaire in our study population.  
 
The patient will be encouraged to make a final decision about screening use in consultation with his provider. The Coach will accompany the patient to his appointment to take notes. At the conclusion of coaching, the patient and provider will receive a document with data collected that reflects the content of the interview and prioritizes questions, values, and goals.  
 
Control Arm: Patients in the control arm will receive the decision aid in the mail and/ or Send Safe Secure 
email prior to the office visit. However, patients in the control arm will not review the decision aid with the Decision Coach. In order to ensure consistent interactions between and among patients in the intervention and control groups, the Coach will offer to patients in the control arm general health coaching using an educational tool focused on dietary and lifestyle modification to reduce the risk of cardiovascular 
disease. Specifically, the Coach will use the American Heart Association’s “Life's Simple 7” educational 
tool, as described above. Health coaching in the control arm will focus on improving the four modifiable health behaviors, including nonsmoking, healthy diet, physical activity, and body mass index (BMI), and the three modifiable biological factors, including blood pressure (BP), total cholesterol, and fasting glucose described in the control educational tool. It is crucial that the control group has some form of interaction with the Coach for an amount of time similar to the intervention group, albeit with a different 
focus, to ensure a sufficient attention control between study arms. Without such an interaction, it would be 
difficult to determine whether the study results were due to the content of the coaching or an extraneous 
experimental effect (e.g., extra time and attention). The Coach will accompany control arm patients to their appointments to take notes. The CHW’s performance will be evaluated to ensure consistency and uniformity. The visits (both intervention and control) will be audio recorded to determine whether the 
quality or content of the discussion differed due to coaching.  
6.1.1  Administration of Intervention 
The intervention will be administered in- person with a CHW -led decision coaching session (1- hour 
minutes). Patient surveys will be administered at 4 different time points: pre- coaching session, post -
coaching session, post clinical appointment, and [ADDRESS_664261] -clinical encounter surveys for each patient participant 
seen. A subsample of patients will be invited to participate in in- depth interviews during the follow -up 
period in an ongoing manner; all provider participants and administrative staff will participate in in- depth 
interviews once patient target enrollment has been reached (study completion).  
 
6.1.[ADDRESS_664262]. Ravenell based on Belkora’s decision coaching protocols.
4 On Day 1, a model of neutral, non- 
directive interviewing designed to elicit and document patient questions  and concerns will be presented.4 
The learning objectives include practice with: low -inference paraphrasing and summarizing; neutral, non-
directive prompting to stimulate patients to elaborate on initial questions and concerns; a general prompt sheet to stimulate an expanded range of patient questions; collaboratively triaging patient issues into strategic, tactical, and logistical categories; and documenting patient questions and concerns into predefined categories to be presented in a consistent format. Drs. Ravenell and Makarov, will observe the 
practice sessions and provide feedback in real -time (e.g. stop the session and explain wh at did not go 
well and how the Coach could have better handled the situation). Finally, there will be weekly and then 
monthly meetings between the Coach and [CONTACT_513124] to discuss any issues. A key component of training is our emphasis that the Coach’s role is not to explain medical evidence or give medical advice. 
Study number:  i18-[ZIP_CODE]   Page 11 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664263], doing so could result in the Coach’s removal from the project (if it recurs and does not stop after 
retraining). Rather, his responsibility is to help patients prepare for talking with their provider by 
[CONTACT_513104][INVESTIGATOR_513091]. The Coach will also help patients determine what their values are in relation to the decision and their values and goals for screening.  
 To ensure quality control in the CHW’s performance, uniformity of experience for the control group participants will be highlighted in the CHW curriculum and emphasized during CHW training sessions. 
Additionally, all coaching sessions will be audio recorded for analysis and so that the study team can 
review them for quality and uniformity using the “Coaching Fidelity and Supervision Checklist”, used previously by [INVESTIGATOR_124]. Fagerlin’s group. We will evaluate the first 10 sessions the CHW conducts in the intervention and control groups and 20% of subsequent coaching sessions. The CHW’s performance will be evaluated to ensure consistency and uniformity. If analysis of the audio recordings reveals significant variation or sub- par performance, the CHW will be retrained and tested before further interaction with 
patients.  
 Lastly, the Coach will collect and record data using the coaching report instrument for the patient to reference during the appointment  
 
6.1.[ADDRESS_664264] Compliance with Study Intervention 
All participants will be included in the data analysis in the arm to which they were randomized, regardless of compliance, intervention received, or deviation from protocol. Data from participants who withdraw will be used to the extent permitted by [CONTACT_513105].  
 
 
7 Baseline Assessment Study Procedures  and Schedule  
7.1  Baseline Study Procedures/Evaluations  
Baseline Data Collection  
Prior to beginning recruitment for the sample size of 228 participants (114/group) , we will b e adapting 
certain methods  from the primary randomized control trial to collect baseline data from clinical  visits to the 
Flatbush Family Health Center.  The purpose of this model is to determine what measures and procedures 
are currently being implemented at the clinic in regards to prostate cancer screening,  prostate cancer risk, 
and any goals and values related to the patient’s decision- making. This model will enroll 20 male patients 
who will be scheduled at the clinic for a routine visit. Inclusion and exclusion criteria’s will remain the same 
as greater study intervention.  
We will prompt patients and providers to discuss Prostate Specific Antigen Screening for the appointment section of the encounter. Patients will be prompted about PSA in the context of their primary care visit . 
Providers will be handed a document with a prompt to identify the patient is part of the study and that PSA should be discussed in the session.  Prompt states the following:  “This patient is enrolled into our study. Please engage him in conversation about PSA testing for prostate cancer screening.”                                          
                      
Audio recording of clinical encounter will remain as a source of data. Consent forms describing this model in detail will be provided to the participant and written documentation of informed consent is required prior to starting baseline data collection. New informed consent form s were created for the patients in regards to 
this encounter. Patients enrolled in this portion of the study will not be randomized later on/ participating in 
either of the main  intervention/control arm.  We will only reimburse the p atients  for their participation and 
for completing follow -up assessments for this baseline. The incentive amounts will remain the same as 
greater study. 
 
 
Baseline Data Collection Specific Procedures  
Patients:   
• Will not receive Decision Aid booklet in the mail.  
Study number:  i18-[ZIP_CODE]   Page 12 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  • Patients will not engage in decision coaching session for PSA screening.  
• All patients will be asked to arrive at their regularly scheduled primary care clinical appointment 
about one hour early to meet with the Decision Coach.  
• Verify inclusion/exclusion criteria.  
• Obtain demographic information, medical history.  
• Obtain informed consent of potential participant verified by [CONTACT_438624]. 
• Patients will be asked to complete surveys only at three  times: pre- coaching session, post -clinical 
appointment, and 6- months follow -up from your appointment.  
• The decision coach will not accompany patient participants to the clinic appointment but will arrange for audio recording of the encounter.  
 
Providers:   
• Providers will consent for both baseline and greater study intervention on the same informed 
consent form.  
• Obtain basic demographic information  
• Providers will not be asked to participate in any survey encounters for this portion of the study.   
 
 
Study Procedures and Schedule  
Study Procedures/Evaluations  
7.1.1  Study Specific Procedures 
Patients:  
• Upon enrollment, patients will be randomized to the control or intervention group. Patients will not 
be informed explicitly which group they are in.  
• All patients will be asked to arrive at your regularly scheduled primary care clinical appointment 
about one hour early to meet with the Decision Coach  or via a HIPAA -compliant platform prior to 
the appointment if the patient prefers to meet remotely . All participants will receive a decision aid 
and educational materials in the mail and/or by [CONTACT_513106].  
• Patients will be asked to complete surveys at 4 time periods: pre- coaching session, post -coaching 
session, post -clinic al appointment, and 3-months follow -up from your appointment.  
• Patients randomized to the intervention arm will engage in decision coaching session for PSA 
screening, including a values clarification exercise. Men in the control group will receive an 
educat ional tool on diet and lifestyle to discuss with the Decision Coach.  
• The Decision Coach will accompany all patient participants to the clinic appointment and audio 
record the encounter  
• A random sub- sample of patient participants will be invited to complete qualitative in- depth 
interviews throughout the study period during follow -up.  
 
Providers: 
• Providers will be asked to complete 2 one- time surveys: one before the study starts and once 
after we reach target enrollment of patient subjects.  
• Providers will be asked to complete a post -encounter survey following the clinical appointment of 
each enrolled patient subject that you treat during the study period. Providers will be blinded to 
randomized group of patient subject.  
Study number:  i18-[ZIP_CODE]   Page 13 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  • Providers will be asked to allow the Decision Coach to accompany enrolled patients to the clinical 
appointment and audio record your encounter with your patients.  
• All participating providers will be asked to complete an in- depth interview (approximately one 
hour) following study completion.  
7.1.[ADDRESS_664265] of Care Study Procedures  
Providers will administer and patients will receive usual care during their primary care clinical appointment.  
7.2 Study Schedule  
7.2.1  Screening  
 
Screening Call (Day -180 to -1)  
• Review medical history to determine eligibility based on inclusion/exclusion criteria.  
• Review medications history to determine eligibility based on inclusion/exclusion criteria.  
• Study staff will review weekly Epic EHR reports of men in the target demographic with upcoming 
clinic appointment s. 
• Study staff will reach out to the patient by [CONTACT_18623]/or in- person at the clinic  to confirm he fits 
enrollment criteria and, if so, will attempt to recruit the patient into the study.   
• After  the telephone call, the patient will be randomized to the CHW intervention or the control arm 
of the study.  
• Men in both groups will be mailed and/or Send Safe Secure emailed a copy of the prostate cancer 
decision aid to review prior to their office visit.  
7.2.2  Enrollment  
 
Enrollment Visit (Day 0) 
• Obtain informed consent of potential participant verified by [CONTACT_438624].  
• Verify inclusion/exclusion criteria.  
• Obtain demographic information, medical history (Patients)  
• Obtain basic  demographic information (Providers) 
• At the office visit, patients in both arms will review the decision aid, including a values clarification 
exercise, with the C oach.  
• For the Intervention group, the C oach will review the content of the mailed and/or emailed 
decision aid and conduct a structured decision counseling session about prostate cancer 
screening.  
• Intervention group: The patient will be encouraged to make a final decision about  PSA screening 
use in consultation with his provider. The C oach will accompany t he patient to his appointment to 
take notes. At the conclusion of coaching, the patient and provider will receive a document with 
data collected that reflects the content of the interview and prioritizes questions, values, and 
goals . 
• Control group: the Coach will offer to patients in the control arm general health coaching using an 
educational tool focused on dietary and lifestyle modification to reduce the risk of cardiovascular 
disease. 
• (Providers) Measures will be collected via brief survey after each pa tient encounter  (the provider 
will be blinded as to whether the patient was in the control or intervention arm) .  
7.2.3  Intermediate Visits  
N/A 
Study number:  i18-[ZIP_CODE]   Page 14 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  7.2.4  Final Study Visit  
 
Survey Administration/Qualitative Interview (Day  180 – 225) 
• (Patients) Time [ADDRESS_664266] -clinic visit  by [CONTACT_648]. If participants do not 
complete the survey within 3 weeks, a second attempt  will be made.  
• If after [ADDRESS_664267] it 
by [CONTACT_648].  
• A subset of patients will be recruited to complete a qualitative interview at [ADDRESS_664268] -clinic visit . 
• (Providers) A final survey will be completed at study completion immediately before the semi -
structured qualitative interview . 
7.2.[ADDRESS_664269] their future interactions with their healthcare providers or employment at the FQHC.  
7.2.6  Unscheduled Visit  
N/A 
7.3 Concomitant Medications, Treatments, and Procedures  
N/A  
7.4 Justification for Sensitive Procedures  
N/A 
7.4.1  Precautionary Medications, Treatments, and Procedures  
N/A 
7.5 Prohibited Medications, Treatments, and Procedures  
N/A 
7.6 Participant Access to Study Intervention at Study Closure  
N/A 
 
8 Assessment of Safety  
8.1 Specification of Safety Parameters  
The Community Health Worker Decision C oach and/or research coordinator staff will give the patient oral 
and written descriptions of the research protocol and will answer any questions the patient may have. The CHW  Decision Coach will also be instructed to offer to read any related study materials to the patients if 
difficulty exists du e to low literacy levels or poor vision. As part of the informed consent process, all 
patients and providers will be reminded that their responses are confidential and that they may refuse to participate in the project or withdraw at any time, and further,  that such an action will in no way affect their 
future interactions with their healthcare providers or employment at the FQHC. After reading and understanding the consent and the procedures, those who choose to participate will sign and date the consent form. All research staff and study personnel will have completed and passed IRB, HIPAA, and extensive human subjects training and will be thoroughly trained in appropriate consent procedures and the precaution to maintain strict confidentiality.  
 
Study number:  i18-[ZIP_CODE]   Page 15 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  The clinic al care of any given participant will be handled entirely by [CONTACT_2299]’s primary care 
provider, and study participants will be made aware of this during enrollment. Similarly, any medical 
problem that arises during study visits will be referred to the participant’s primary care provider.  
 
In compliance with HIPAA, individual participant confidentiality is assured through the use of ID codes, assigned by [CONTACT_30165]. These ID numbers will not contain any protected health information (PHI). Data collection forms will be identified only with IDs; relating of ID code to names will require protected information supervised by a designated high- level staff member. None of the analyses will permit 
individual identification.  
 Hard copy data will be kept in a locked storage area in a locked office and building. Electronic data will be 
password- protected, stored only on a secure server, and backed up frequently. Only designated 
members of the study team will have access to Protected Health Information (PHI) and a variety of precautions will be taken to ensure the security of participant data.  
 
8.1.1  Definition of Adverse Events (AE)  
An adverse event  (AE) is any symptom, sign, illness or experience that develops or worsens in severity 
during the course of the study.  Intercurrent illnesses or injuries should be regarded as adverse events.  
Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests 
• is considered by [CONTACT_1372] 
 
8.1.2  Definition of Serious Adverse Events (SAE)  
 
Serious Adverse Event  
Adverse events are classified as serious or non- serious.  A serious adverse event  is any AE that is:  
• fatal 
• life-threatening  
• requires or prolongs hospi[INVESTIGATOR_4408]  
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medi cal event  
 Important medical events are those that may not be immediately life threatening, but are clearly of major 
clinical significance. They may jeopardize the subject, and may require intervention to prevent one of the other serious outcomes noted above.  For example, drug overdose or abuse, a seizure that did not result in in-patient hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department would 
typi[INVESTIGATOR_15355].  
 
All adverse events that do not meet any of the  criteria for serious should be regarded as non -serious 
adverse events.  
8.1.3  Definition of Unanticipated Problems (UP)  
 Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all  of
  the following criteria:  
• Unexpected in nature, severity, or frequency   (i.e. not described in study -related documents such 
as the IRB -approved protocol or consent form, the investigators brochure, etc.)  
Study number:  i18-[ZIP_CODE]   Page 16 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  • R elated or possibly related to participation in the research (i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_9156])  
• Suggests that the research places subjects or others at greater risk of harm  ( including physical, 
psycho logical, economic, or social harm).  
 
8.2 Classification of an Adverse Event  
8.2.1  Severity of Event  
The Principal Investigators are responsible for reporting adverse events to the NYU IRB, the entity granting IRB approval. Adverse events (AEs) and serious adverse events (SAEs) that are severe in nature and could 
potentially affect the well -being of study participants will be reported to IRB immediately  
 
For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life- threatening or incapacitating.  
 
8.2.2  Relationship to Study Intervention  
 For all collected AEs, the clinician who examines and evaluates the participant will determine the AE’s 
causality based on temporal relationship and his/her clinical judgment. The degree of certainty about causality will be graded using the categories below.  
• Definitely Related  – There is clear evidence to suggest a causal relationship, and other possible 
contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to intervention administration and cannot be explained by [CONTACT_9153]. The response to withdrawal of the intervention (dechallenge) should be clinically plausible.  
• Probably Related  – There is evidence to suggest a causal relationship,  and the influence of other 
factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the intervention, is unlikely to be attributed to concurrent disease or other drugs or chemicals, and follows a clinically reasonable response on withdrawal (dechallenge). Rechallenge information is not required to fulfill this definition.  
• Possibly Related  – There is some evidence to suggest a causal relationship (e.g., the event 
occurred within a reasonable time after administration of the trial intervention). However, other 
factors may have contributed to the event (e.g., the participant’s clinical condition, other 
concomitant events). Although an AE may rate only as “possibly related” soon after discovery, it 
can be flagged as requiring more information and later be upgraded to “probably related” or “definitely related,” as appropriate.  
• Unlikely to be related  – A clinical event, including an abnormal laboratory test result, whose 
temporal  relationship to intervention administration makes a causal relationship improbable (e.g., 
the event did not occur within a reasonable time after administration of the trial intervention) and in which other drugs or chemicals or underlying disease provides  plausible explanations (e.g., the 
participant’s clinical condition, other concomitant treatments).  
• Not Related  – The AE is completely independent of study intervention administration, and/or 
evidence exists that the event is definitely related to another etiology. There must be an alternative, definitive etiology documented by [CONTACT_15370].  
Study number:  i18-[ZIP_CODE]   Page 17 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  8.2.3  Expectedness 
Danil V. Makarov will be responsible for determining whether an AE is expected or unexpected. An AE 
will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the 
risk information previously described for the study inter vention.  
 
8.3 Time Period and Frequency for Event Assessment and Follow -Up 
 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate RF. Information to be collected includes event description, time of onset, clinician’s assessment of severity, relationship to study intervention (assessed only by [CONTACT_12213] a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while on 
study must be documented appropriately regardless of relationship. All AEs will  be followed to adequate 
resolution.  
 Any medical condition that is present at the time that the participant is screened will be considered as baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time 
during the study, it will be recorded as an AE. UPs will be recorded in the data collection system 
throughout the study.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
 The PI [INVESTIGATOR_15356] 7 (for non- serious AEs) or 30 days (for SAEs) after the last day of study participation. At 
each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization.   
 
All unresolved adverse events should be followed by [CONTACT_1374], the 
subject is lost to follow -up, or the adverse event is otherwise explained.  At the last scheduled visit, the 
investigator should instruct each subject to report any  subsequent event(s) that the subject, or the 
subject’s personal physician, believes might reasonably be related to participation in this study.  The investigator should notify the study sponsor of any death or adverse event occurring at any time after a 
subject has discontinued or terminated study participation that may reasonably be related to this study.  
 
8.4 Reporting Procedures – Notifying the IRB  
8.4.1  Adverse Event Reporting 
The Principal Investigators are responsible for reporting adverse events to the NYU IRB, the entity granting IRB approval. Adverse events (AEs) and serious adverse events (SAEs) that are severe in nature and could 
potentially affect the well -being of study participants will be reported to IRB immediately. The contact -PI 
([CONTACT_513125]) will summarize AEs and SAEs in annual continuation reports. The PIs will create a detailed plan to address serious events that may occur during the study period. The clinical providers will be conducting any clinical evaluations that occur during the study visit and will administer usual care.  
.. The PIs and Co- Investigators will meet biannually to review adverse event reports, participant complaints, 
and dropout rates.  
8.4.2  Serious Adverse Event Reporting- 
 
Study number:  i18-[ZIP_CODE]   Page 18 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  The Principal Investigators are responsible for reporting adverse events to the NYU IRB, the entity granting 
IRB approval. Adverse events (AEs) and serious adverse events (SAEs) that are severe in nature and could 
potentially affect the well -being of study participants will be reported to IRB immediately .  
 
We expect the level of risk due to this intervention to be minimal as no invasive measures or procedures 
are proposed. Providers will administer and patients will receive usual care during their clinical appointment.  
 
8.4.3  Unanticipated Problem Reporting  
Incidents  or events that meet the OHRP criteria for UPs require the creation and completion of an UP 
report form. It is the site investigator’s responsibility to report UPs to their IRB and to the DCC/study sponsor. The UP report will include the following informat ion: 
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP.  
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
 
• UPs that are SAEs will be reported to the IRB and to the DCC/study sponsor within 48 hours of 
the investigator becoming aware of the event.  
• Any other UP will be reported to the IRB and to the DCC/study sponsor within 1 week of the 
investigator becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s written reporting procedures), the supporting agency head (or designee), and OHRP within 1 wee of the the IR’s receipt of the report of the problem from the investigator.  
8.5 Reporting Procedures – Notifying the Study Sponsor  
The study clinician will complete a SAE Form within the following timelines:  
 
• All deaths and immediately life- threatening events, whether related or unrelated, will be recorded 
on the SAE Form and submitted to the DCC/study sponsor within [ADDRESS_664270] information.  
• Other SAEs regardless of relationship will be submitted to the DCC/study sponsor within 72 hours of site awareness.  
 All SAEs will be followed until satisfactory resolution or until the site investigator deems the event to be 
chronic or the adherence to be stable. Other supporting documentation of the event may be requested by 
[CONTACT_15791]/study sponsor and should be provided as soon as possible.  
 As a follow -up to the initial report, within the following [ADDRESS_664271] the understanding of the event.  Significant new 
information on ongoing unanticipated adverse  effects shall be provided promptly to the study sponsor.  
 
8.6 Study Halting Rules  
If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_33894](s) for the termination or suspension.  
 
Study number:  i18-[ZIP_CODE]   Page 19 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  Circumstances that  may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
• Determination of futility  
8.7 Safety Oversight  
 
It is the responsibility of the Principal Investigator [INVESTIGATOR_30900].  This 
safety monitoring will include careful assessment and appropriate reporting of adverse events as noted above, as well as the construction and implementation of a site data and safety -monitoring plan . Medical 
monitoring will include a regular assessment of the number and type of serious adverse events.  
 Safety oversight will be under the direction of a DSMB composed of individuals with the appropriate expertise, including statistician (distinct from the project statistician) and two pedagogical experts (distinct 
from study personnel. The DSMB will meet annually to assess safety and efficacy data on each arm of the study. The DMSB will operate under the rules of an approved charter that will be written and reviewed at the organizational meeting of the DSMB. At this time, each data element that the DSMB needs to assess will be clearly defined. The DSMB will provide its input to NIH.  
 
[ADDRESS_664272] of the 
trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory requirement(s).  
 
• The clinical providers will be conducting any clinical evaluations that occur during the study visit and will administer usual care. However, in the event that the Research Coordinator finds a high PSA result during time of  post 6 month follow -up (defined as PSA> 4, which is indicative of 
potential risk for  prostate cancer), the RC will check to see if the patient has since followed up 
with his provider; if not: the study team will contact [CONTACT_513107] 
(In Basket) and urge the provider to have a consultation with the patient.  
 
 
10 Statistical Considerations  
10.1 Statistical and Analytical Plans  
An "intent -to-treat" (ITT) approach will be used to assess the hypotheses. All participants will be included 
in the data analysis in the arm to which they were randomized, regardless of compliance, intervention received, or deviation from protocol. Data from participants who withdraw will be used to the extent 
permitted by [CONTACT_513105].  
 
A descriptive analysis of all data collected will be performed using graphical and numerical exploratory data techniques. These preliminary analyses will be used to: (1) assess data quality and completeness; (2) describe univariate and bivariate distributions at each time point; and (3)  identify associations between 
variables. We will identify features of the data that may necessitate special methods (e.g. excess zeroes, 
missing data, departures from distributional assumptions). During preliminary analysis we will examine: 
(1) comparability of study arms at baseline (based on Chi- squared statistics or t -tests, as appropriate), (2) 
Study number:  i18-[ZIP_CODE]   Page 20 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  relationships between the response variables and potential covariates, and (3) predictors of missing 
data/drop- out. 
 We will use linear mixed models (for continuous outcomes), logistic generalized linear mixed models (for binary outcomes), and random effects multinomial models (for outcomes with more than two levels, such as adherence). In  all  models,  time  (2  dummy  variables)  and  intervention  will  be  included  as  fixed  effects; provider will be a random effect. The intervention effect of interest is the treatment X time interaction. Identified predictors of missing data will be included as covariates in this random effects 
framework, to provide unbiased estimates of the intervention effect under an assumption of missing at 
random (i.e. missingness depends only on observed - not on unobserved - covariates). We will conduct 
sensitivity analyses to assess plausible departures from this assumption. Other demographic and clinical covariates will be included as necessary in adjusted analyses. Model assessment will be conducted using appropriate regression diagnostics. The primary and secondary analyses will be done using Stata and SAS, and MPlus will be used in the mediation analyses.  
 
10.2 Patient Survey Outcome Variables: Patient Demo graphics, Clinical Features 
and Preferences:  
Demographics : We will collect baseline information known to be associated with utilization of PSA 
screening including age, race, marital status, highest education level, yearly income, and insurance status.
 
Clinical Features: The International Prostate Symptom Score22 (IPSS) is an 8- item scale to assess the 
severity of prostate- related symptoms and quality of life. IPSS has high internal consistency (Cronbach's α 
= 0.86) and excellent test -retest reliability (r = 0.92). Patient overall health will be self -assessed on a 0- 5 
scale ranging from “very poor” to “excellent”. These survey data will be supplemented by [CONTACT_513108]. 
Literacy and Numeracy:  We will measure literacy using the REALM23, a word recognition task that 
measures reading level and classifies patients as having adequate or inadequate literacy. To assess patients’ numerical skills we will use the 8- item Subjective Numeracy Scale,
24,[ADDRESS_664273]: The Trust in Physicians Scale (TIPS) has 11- items that quantify a patient’s interpersonal trust in his 
physician. 26 This scale is valid and reliable (Cronbach’s α =0.85). The Health Care System Distrust Scale 
is [ADDRESS_664274] of the health care system. It 
is valid and reliable (Cronbach’s α =0.75).  
Preference for shared decision- making:  We will measure patients’ desire to participate in SDM using an 
adaptation of Degner & Sloan's commonly used Control Preference Scale, which asks patients whether they want to make the decision alone, with their provider, or have their provider make it.
28 
 
Experience with Decision Coaching Program : A survey developed by [CONTACT_513109]’s overall experience with the decision- coaching program. The survey consists of [ADDRESS_664275] of the CHW intervention on the patient and the appointment.  
10.3 Statistical Hypotheses 
Decision Quality (Hypothesis 1.1):  We will use an objective measure of decision quality consisting of 
two components as defined by [CONTACT_406043].: 1) being informed (e.g. accurate understanding about 
screening and its risks and benefits) and 2) making pref erence- concordant decisions (i.e. treatment 
consistent with patient preferences as determined by [CONTACT_513110]).7 
 
Knowledge : We will use  a survey developed by [CONTACT_513111] (Appendix F).8 The survey was pi[INVESTIGATOR_513092], [LOCATION_001] enrolled in a study to help determine whether PSA screening was  right for them.  
 
Study number:  i18-[ZIP_CODE]   Page 21 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  Informed Choice : The Measure of Informed Choice evaluates the screening decision. It assesses 
knowledge, it is consistent with the decision- maker's values, and it is behaviorally implemented. The 
measure consists of [ADDRESS_664276] uptake.29 A Decisional Balance Scale will assess the patient’s attitudes towards PSA 
testing. The scale consists of a six item pros scale (alpha = 0.87) and six item cons scale (alpha = 0.82) scored on a 5- point Likert scale (strongly agree to strongly disagree).
30 
 
Perception of Quality of Care (Hypothesis 1.2): Patient perception of quality of care will be assessed 
along the domains of communication, decisional self -efficacy, and self -efficacy in communicating with 
their provider, satisfaction and decisional conflict. These domains represent some benefits for patients 
engaging in SDM.9 
 
Communication: Combined Outcome Measure for Risk communication And treatment Decision- making 
Effectiveness (COMRADE) is a 20- item measure validated for clinical encounters.10 Its sub- scales are 1) 
satisfaction with physician communication and 2) patient confidence in the decision. The scale has 
excellent internal consistency (Cronbach’s α =0.92). Additionally, the Questionnaire Concerning the 
Doctor -Patient Communication Skills will be used.11 This validated 19 item scale captures process 
(greeting, listening) and content (explanations and next steps) aspects of the visit from the provider’s and patient’s perspectives.  
 
Self-efficacy: The Decision Self -Efficacy Scale is an 11 -item scale measuring self -efficacy to perform 
informed decision- making (e.g., getting needed information, asking questions, expressing opi[INVESTIGATOR_6153], and 
asking for advice).
31 The Perceived Efficacy in Patient -Physician Interactions is a 10- item scale 
measuring self -efficacy for provider communication.12 The scale is reliable (Cronbach’s α=0.91) and valid 
in older adults.  
 
Satisfaction with Decision: The SWD is a 6- item measure assessing patient satisfaction with their decision 
and decision- making process. The scale has been used in several hundred studies and has good internal 
consistency (Cronbach’s α=0.87).13 The Decisional Regret Scale is a validated, 5- item scale measuring 
regret or remorse following a health care decision.14 It has good internal consistency (Cronbach’s α=0.81 
to 0.92).  
 Difficulty and Decisional Conflict : The Decisional Conflict Scale will measure patients’ perceptions of 1) 
uncert ainty in choosing options, 2) feelings of having adequate knowledge and clear values, and 3) 
effective decision- making.
32  It is reliable (α ranged from 0.78 to 0.92) and its test- retest reliability 
coefficient is 0.81.  
 
Measurement of Impact on PSA Screen ing (Hypothesis 1.3): Three months post -intervention, we will 
collect patient survey data, including self -reported PSA testing. After six months post -intervention, w e will 
also extract patient -level EHR data on PSA test utilization. We will then test the association between PSA 
utilization and intervention exposure.  
 Provider Survey Variables:  Demographics and Preferences  
Demographics : We will collect age, gender, race/ethnicity, year of medical school graduation, years since 
completion of residency, and fraction of time spent in direct patient care.  
Preferences : We will assess providers’ practice style through the Evidence- Based Practice Attitude 
Scale.
33 This 5 -domain, 15- item scale assesses providers’ feelings toward adopting new practices with 
good int ernal consistency (Cronbach’s α = 0.90- 0.59.)  
Provider Experience (Hypothesis 2.1) :  
Satisfaction : The Physician Satisfaction Scale designed for encounter -specific situations measures 
satisfaction.34 The survey has 2 dimensions and 16 items measuring understanding of the patient's 
problem, perceiving patient comprehension, and affective reactions. Internal consistency is good 
(Cronbach α=0.85).  
Study number:  i18-[ZIP_CODE]   Page 22 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  Difficulty:  The Mental Work -Load Instrument assesses difficulty with the subjective experience or cost 
incurred by  a physician in performing patient care.35 The survey has 5 dimensions and 6 items addressing 
mental effort, physical effort, difficulty, performance and stress. Internal consistency is good (Cronbach 
α=0.80).  
Communication:  We reuse Questionnaire Concerning the Doctor -Patient Communication Skills from 
C8.2.11 
10.4 Analysis Datasets  
An "intent -to-treat" (ITT) approach will be used to assess the hypotheses posited in the Aims. All 
participants will be included in the data analysis in the arm to which they were randomized, regardless of 
compliance, intervention received, or deviation from protocol. Data from participants who withdraw will be 
used to the extent permitted by [CONTACT_513105].  
10.5 Description of Statistical Methods  
10.5.1  General Approach  
Statistical Analysis Plan:  An "intent -to-treat" (ITT) approach will be used to assess the hypotheses posited 
in the Aims section. All participants will be included in the data analysis in the arm to which they were randomized, regardless of compliance, intervention received, or deviation from protocol. Data from participants who withdraw will be used to the extent permitted by [CONTACT_513105].   
A descriptive analysis of all data collected will be performed using graphical and numerical exploratory data 
techniques. These preliminary analyses will be used to: (1) assess data quality and completeness; (2) describe univariate and bivariate distributions at each time point; and (3) identify associations between variables. We will i dentify features of the data that may necessitate special methods (e.g. excess zeroes, 
missing data, departures from distributional assumptions). During preliminary analysis we will examine: (1) comparability of study arms at baseline (based on Chi -squared statistics or t -tests, as appropriate), (2) 
relationships between the response variables and potential covariates, and (3) predictors of missing data/drop- out.  
We will use linear mixed models (for continuous outcomes), logistic generalized linear mixed models (for binary outcomes), and random effects multinomial models (for outcomes with more than 2 levels, such as adherence). In all models, time (2 dummy variables) and intervention will be included as fixed effects; provider will be a random effect. The intervention effect of interest is the treatment X time interaction. 
Identified predictors of missing data will be included as covariates in this random effects framework, to provide unbiased estimates of the intervention effect under an assumption of missing at random (i.e. missingness depends only on observed - not on unobserved - covariates). We will conduct sensitivity 
analyses to assess plausible departures from this assumption. Other demographic and clinical covariates will be included as necessary in  adjusted analyses. Model assessment will be conducted using appropriate 
regression diagnostics. The primary and secondary analyses will be done using Stata and SAS, and MPlus will be used in the mediation analyses.  
10.5.2  Analysis of the Primary Endpoint(s)  
Our primary outcomes of interest are knowledge and PSA screening rates. Knowledge will be measured 
once after decision coaching. This approach prevents patients from preferentially learning the questions 
from the knowledge pre- test. For other measures in hypotheses 1.[ADDRESS_664277] coaching 
and whether those changes are sustained at Times 3 and 4. A random effects (generalized) linear regression model will be used to test absolute and time -specific differences attributable to the intervention. 
In additional analyses, we will adjust for other covariates which may be unbalanced between the 
intervention arms at baseline at p=0.10. For hypothesis pertaining to patients’ perception of care quality, 
Study number:  i18-[ZIP_CODE]   Page 23 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664278] 
in separate analyses of control and Intervention groups to examine possible associations between those 
measurements and outcomes.  
10.5.3  Analysis of the Secondary Endpoint(s)  
We will evaluate the effect of intervention assignment on provider experience using a random effects (generalized) linear regression model as in Aim 1. Provider will be the random effect.  We will also 
investigate the specific provider experience with each patient group separately and compare the experience across all the participating providers. A qualitative analyst, trained on using the “Observing patient involvement in decision making” (“OPTION”) scoring method (Appendix E) will assign ratings to transcripts of the physician- patient encounter. A second researcher will independently assign ratings, and reliability 
will be assessed based on the Kappa agreement statistic. When ratings achie ve a Kappa >0.80, the analyst 
will continue to rate the encounters. The 2nd rater will continue to rate 5% of the remaining encounters to ensure continued reliability. We will test the hypothesis that patient conversational involvement (determined by [CONTACT_513112]) and physician facility with discussing screening (determined by [CONTACT_513113]) is 
associated with the patient decision quality.
 
10.5.4  Safety Analyses  
Adverse events (AEs) and serious adverse events (SAEs) that are severe in nature and could potenti ally 
affect the well -being of study participants will be reported to IRB immediately. In addition, the contact -PI 
([CONTACT_513125]) will summarize AEs and SAEs in annual continuation reports. The PIs will create a detailed plan to address serious events that may occur during the study period. The clinical providers will be 
conducting any clinical evaluations that occur during the study visit and will administer usual care.  
The PIs and Co- Investigators will meet biannually to review adverse event reports, participant complaints, 
and dropout rates.  
10.5.[ADDRESS_664279] education level, yearly income, and insurance status.  
 
During preliminary analysis we will examine: (1) comparability of study arms at baseline (based on Chi -
squared statistics or t -tests, as appropriate), (2) relationships between the response variables and 
potential covariates, and (3) predictors of missing data/drop- out. 
 
10.5.7  Planned Interim Analysis  
N/A 
[IP_ADDRESS]  Safety Review - N/A 
 
[IP_ADDRESS]  Efficacy Review  
N/A 
10.5.[ADDRESS_664280] under an assumption of missing at random (i.e. missingness depends  only on observed - not on unobserved - covariates). We will conduct sensitivity 
Study number:  i18-[ZIP_CODE]   Page 24 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  analyses to assess plausible departures from this assumption. Other demographic and clinical covariates 
will be included as necessary in adjusted analyses.  
 
10.5.9  Multiple Comparison/Multiplicity  
N/A 
10.5.10  Tabulation of Individual Response Data  
N/A 
10.5.[ADDRESS_664281]: We will determine the cost of a CHW -led decision coaching program and its effect on prostate cancer 
screening costs. According to theoretical models for dissemination and implementation, understanding cost 
is critical to future implementation. The costs of research- related activities will not be included in estimates 
of intervention costs. All costs will be summarized and confidence intervals calculated.  
 Program Costs: We will estimate the cost of implementing CHW -led decision coaching using methods 
described by [CONTACT_279131]. in their paper documenting organizational costs for implementing a depression care quality improvement intervention into primary care practices. These methods allow for the documentation of organizational costs associated with the program itself, not just the costs associated with changes in 
patient care, whose calculation we describe below. We will collect data on participant hours and 
intervention-r elated activities directly related to the program’s implementation. Implementation costs are 
related to travel, clinical informatics, provider training sessions, conference calls, development of training materials, email communication, and any other activities spent counseling, training, or supporting personnel at the study site. Participants will include any individual (provider, CHW, study staff, administrator) participating in the program. Data sources used for estimating CHW program costs are described in Section  
 Healthcare Utilization Costs: We will summarize costs for select screening procedures directly related to prostate cancer screening based on identification in diagnosis and procedure codes, as described by [CONTACT_6283]. Gold and Makarov. Screening care  activities will be ascertained beginning with the initial clinic visit and any 
related care received up to one year later. We will tally costs for PSA screening and downstream procedures. PSA -based screening will be determined using specific Healthcare Common Procedure 
Coding System (HCPCS) codes: G0103, [ZIP_CODE], [ZIP_CODE], and [ZIP_CODE]. Biopsies will be restricted to prostate biopsies that were done within [ADDRESS_664282].  
 Qualitative Aim: We will  use qualitative methods to identify and describe attitudes and perceptions of Black 
men and their providers relating to PSA testing, the CHW -led decision coaching intervention, and SDM. We 
will conduct in- depth, semi structured interviews with both groups. Interviews will be audio recorded and 
transcribed for thematic analysis. The study population will be patients from the intervention group, their providers, and two administrative leaders at the study site. Patients will be enrolled in the qualitative portion of the study throughout the study period. We will enroll all site providers who care for adult men and participated in the intervention (n=5) and administrative leadership (n=2). Providers (5) include two full -time 
Family Nurse Practitioners (FNPs), one full time medical/pediatric provider (MD), and two family medicine 
providers (MD). We will exclude providers who do not care for adult men, since our focus is prostate cancer. At study initiation, investigators will interview each of the participating providers and administrators to document and analyze attitudes towards and perceptions of the intervention. These interviews will then be 
Study number:  i18-[ZIP_CODE]   Page 25 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  conducted every 6 months thereafter. During these interviews, the investigators will take detailed field notes 
to document responses as an additional source of qualitative data  
10.6 Sample Size  
Sample Size Justification: In determining the recruitment target, we considered the 1) detectable group differences in patient knowledge and decision quality based on pi[INVESTIGATOR_9958], 2) differences in PSA screening rates between the control and intervention groups, and 3) expected drop out. In our PSA pi[INVESTIGATOR_799], the group means of knowledge change are 2.6 (SD=2.81) and 5.1 (SD=3.19) in the control and intervention groups respectively. Using the proposed sample size and the above listed group standard deviations and assuming our control and CHW group have no knowledge difference at baseline, we are 
able to detect a 1.[ADDRESS_664283] with 
80% power and 5% significant level. Comparing to the observed knowledge improvement group difference 
(2.6 in the pi[INVESTIGATOR_799]) we would have excellent power for this goal. Conservatively assuming a 20% drop out, we will recruit 228 partici pants (114/group) to achieve a final sample of 182 (91/group). Based on 
current clinic screening rates provided by [CONTACT_332127], we assume the post -intervention PSA 
screening rate will be 30% (unchanged from baseline) in the control group and 50% (consistent with current 
general screening rates among Medicare beneficiaries) in the intervention group.[ADDRESS_664284] for two proportions, a total group of 182 subjects with 91 subjects in each group can achieve 80% 
power to detect a 20% difference in the post -intervention PSA screening rate between control and CHW 
groups with 5% significance level.   
10.7 Measures to Minimize Bias  
10.7.1  Enrollment/Randomization/Masking Procedures 
 Randomization Scheme:  The independent randomization process will be implemented within each provider. To further consider the possible confounding effect of age, we will divide the participants from each provider into two strata: 40-54 years and 55- 69 years. Within each stratum, patients (4 person 
blocks) will be randomized with a computer -generated permuted block random number to control or 
intervention upon enrollment. Healthcare providers, the statistician and research staff who assess study outcomes will be blinded with regard to whether a participant was randomized to the intervention or to the 
control group  
10.7.2  Evaluation of Success of Blinding  
It may not be possible to blind providers completely, especially with the CHW Decision C oach’s presence 
at the clinic visit. Discussion between c oach and patient may reveal their previous interaction. Providers 
may thus be prompted to engage in greater SDM than they would outside of the study.  Providers will be 
handed a document with a prompt to identify the patient is part of the study and that PSA should be 
discussed in the session.  Prompt states the following: “This patient has been enrolled into our study. 
Please engage him in conversation about PSA testing for prostate cancer screening.”                                                                            
”  However, if this occurs it would bias us toward the null and make a Type I error less likely.  
10.7.3  Breaking the Study Blind/Participant Code  
In the event that the Research Coordinator finds a critical PSA result during time of post 6 month follow -
up (defined as PSA> 4, which is indicative of potential risk of  prostate cancer), the RC will check to see if 
the patient has since followed up with his provider; if not: the study team will contact [CONTACT_513114] a consultation with the patient.  
11 Source Documents and Access to Source Data/Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in 
source documents.  Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], 
Study number:  i18-[ZIP_CODE]   Page 26 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copi[INVESTIGATOR_19093], microfiches, photographic negatives, microfilm 
or magnetic media, x -rays, subject files, and records kept at the pharmacy, at the laboratories, and at 
medico- technical departments involved in the clinical trial.   
 The study case report form (CRF) is the primary data collection instrument for the study.  All data requested on the CRF must be recorded.  All missing data must be explained.  If a space on the CRF is 
left blank because the procedure was not done or the question was not asked, write “N/D”.  If the item is 
not applicable to the individual case, write “N/A”.  All entries should be printed legibly in black ink.  If any entry error has been made, to correct such an error, draw a single straight line through the incorrect entry and enter the correct data above it.  All such changes must be initialed and dated.  DO NOT ERASE OR WHITE OUT ERRORS.  For clarification of illegi ble or uncertain entries, print the clarification above the 
item, then initial and date it.  
 Study information will be entered into REDCap survey forms. All data fields will be entered using free text and multiple- choice entries with reminders to ensure fields are entered appropriately. REDCap has data 
auditing to ensure any changes to data are recorded and justified.  
 Access to study records will be limited to IRB -approved members of the study team. The investigator will 
permit study -related monitoring, audits, and inspections by [CONTACT_1201]/EC , the sponsor, government 
regulatory bodies, and University compliance and quality assurance groups of all study related documents (e.g. source documents, regulatory documents, data collection instruments, study data etc. ).  
The investigator will ensure the capability for inspections of applicable study -related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.).  
 Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_17256].  
 
12 Quality Assurance and Quality Control  
 QC procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will  be generated. Any missing data or data anomalies will be communicated to the 
site(s) for clarification/resolution.  
 Following written SOPs, the monitors will verify that the clinical trial is conducted and data are generated, documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482].  
13 Ethics/Protection of Human Subjects  
13.[ADDRESS_664285]  
 
Study number:  i18-[ZIP_CODE]   Page 27 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and the consent form must be 
obtained before any participant is enrolled. Any amendment to the protocol will require review and 
approval by [CONTACT_3484]. All changes to the consent form will be IRB approved; a determination will be made regarding whether previously consented participants need to be re- consented.   
13.3 Informed Consent Process . 
13.3.1  Consent/Assent and Other Informational Documents Provided to Participants  
Consent forms describing in detail the study intervention, study procedures, and risks are given to the participant and written documentation of informed consent is required prior to starting intervention. The following informed consent form is submitted with this protocol, for both patients and providers.  
13.3.2  Consent Procedures and Documentation  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participants and their families. Consent forms will be IRB -
approved and the participant will be asked to read and review the document. The investigator will  explain 
the research study to the participant and answer any questions that may arise. All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Participants will have the opportunity to carefully review the written consent form and ask questions prior to signing. The participants should have the opportunity to discuss the study with their surrogates or think about it prior to agreeing to participate.  
 
Due to COVID -19 and to keep the safety of both our research team and research subjects, we will be 
collecting consent via telephone or WebEx . A trained Research Assistant will schedule a time with eligible 
interested part icipants to go over the written consent via telephone or WebEx . Research Assistants will 
email or mail a copy of the consent to participants in preparation for the telephone consent. After going over 
the written consent via telephone, research assistants w ill also send the consent via a RedCap link  where 
the participant has the opportunity to read a copy of the written consent and sign electronically, confirming that they read and understood the consent. Research Assistants will also document on RedCap the time 
and date of the telephone consent and note that the consent process was done via telephone due to COVID -19. The completed ICF will be returned via REDCap. Upon receipt of the signed ICF, SC will 
schedule the coaching session  by [CONTACT_513115] (such as webex). Upon signing the consent form 
participants will be assigned a participant ID number that will be used to identify their interview and all other 
documents related to their participation.  Additionally, they will be assigned  a pseudonym for reporting 
purposes.  
 
Consent forms will include the participant’s name [CONTACT_513123] [CONTACT_513116], prior to the collection of any data. For remotely conduced ICF appo intments, the study staff obtaining consent will document having witnessed the consent by [CONTACT_2960] a 
hard copy of a progress note to be mailed to and stored at the site in the study records.  
 
Remote interviews conducted and recorded by [CONTACT_513117].  
 
The participant will sign the informed consent document prior to any procedures being done specifically for 
the study. Subjects will sign written full informed consent and audio consent form prior to enrollment in the 
study. These forms will be administered and hand written digital sign atures will be collected with a study 
iPad or tablet, witnessed by a Community Health Worker . The participants may withdraw consent at any 
Study number:  i18-[ZIP_CODE]   Page 28 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664286]’s research record. The consent process, including the name [CONTACT_21811], will be thoroughly documented in the subject’s research record. Any alteration to the standard consent process (e.g. use of a translator, 
consent from a legally authorized representative, consent document presented orally, etc.) and the 
justification for such alteration will likewise be documented.  
 The iPad/ tablet devices used in this research will have security features that are designed to protect the 
device and data while enforcing strict network and platform security. These are:  
 
1. Device protection  
 Strong passwords  
 Passcode expi[INVESTIGATOR_513093] -the-air passcode enforcement  
 Progressive device protection  
 
2. Data protection   Remote and local wipe  
 Encrypted configuration profiles  
 Encrypted iTunes backup  
 Hardware encryption  
 
3. Network Security  
 Cisco IPSec, L2TP, PPTP VPN protocols  
 SSL/TLS with X.509 certificates  
 WPA/WPA2 Enterprise with 802.1X  
 Certificate -based authentication  
 RSA SecurID, CRYPTOCard  
 
4. Platform security  
 Runtime protection  
 Mandatory code signing  
 Keychain services  
 Common crypto APIs  
The extensive precautions available to iPads will minimize the risk involved with maintaining research databases on portable devices. Furthermore, the device is a conduit that passes data to 
the cloud storage site, so only information from the current records are locally stored until the web 
is accessed through the cellular network.  
  All research protocols will be reviewed and approved by [CONTACT_513118] (IRB) prior to gaining access to personal health information (PHI) and participant recruitment. The Community 
Health Worker Decision Coach will give the patient oral and written descriptions of the research protocol 
and will answer any questions that the patient may have. The CHW Decision Coach will also be instructed to offer to read any related study materials to the patients if difficulty exists due to low literacy 
levels or poor vision. As part of the informed consent process, all patients and providers will be reminded that their responses are confidential and that they may refuse to participate in the project or withdraw at 
any time, and further, that such an action will in no way affect their future interactions with their healthcare 
providers or employment at the FQHC. After reading and understanding the consent and the procedur es, 
those who choose to participate will sign and date the consent form. All research staff and study 
Study number:  i18-[ZIP_CODE]   Page 29 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664287] 
qualitative interviews.   
 
Providers: During recruitment communications, the study team may set up a brief in- person meeting to 
review details related to informed consent. These meetings will occur in private offices to ensure confidentiality. Study staff will remind providers that participation is voluntary and all responses and study outcomes will be de- identified, reported as aggregate and identifying data or responses will not be shared 
with institutional leadership. Providers will consent to the study in its entirety prior to recruitment of 
patients. Audio consent will also be obtained to audio record clinical encounters and conduct qualitative interviews.  
 
13.[ADDRESS_664288] of 1996 (HIPAA).  Those regulations require a signed subject authorization informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study  
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains the ability to use all information collected prior to the revocation of subject authorization.  For 
subjects that have revoked authorization to collect or use PHI, attempts should be made to obtai n 
permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study 
period.  
 Participant confidentiality is strictly held in trust by [CONTACT_3486], their staff, and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples and 
genetic tests in addition to the clinical information relating to participants. Therefore, the study protocol, 
documentation, data, and all other information generated will  be held in strict confidence. No information 
concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.  
The study monitor, other authorized representatives of the sponsor, or representatives of the IRB may 
inspect all documents and records required to be maintained by [CONTACT_093], including but not limited 
to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site will permit access to such records.  
 The study participant’s contact [CONTACT_10414]. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by [CONTACT_46202].  
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be transmitted to and stored at the NYU School of Medicine. This will not include the participant’s contact [CONTACT_1290]. Rather, individual participants and their research data will be identified by a unique study identification number. The study data entry and study management systems used by [CONTACT_513119]. At the end 
of the study, all study databases will be de- identified and archived at the NYU School of Medicine.  
Study number:  i18-[ZIP_CODE]   Page 30 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: [ADDRESS_664289] access to research records to refuse to disclose identifying information on research participation in any civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, or local level. By [CONTACT_175319], Certificates of Confidentiality help achieve 
the research objectives and promote participation in studies by [CONTACT_4205][INVESTIGATOR_306219].  
13.4.1  Research Use of Stored Human Samples, Specimens, or Dat a 
N/A 
13.5 Future Use of Stored Specimens  
N/A 
 
[ADDRESS_664290] Keepi[INVESTIGATOR_007]  
14.1 Data Collection and Management Responsibilities  
 
Study personnel will access demographics, PSA use and Gleason score using Epic. Data will be stored locally and backed up on a secure server. Statistical analyses will be performed using SAS 9.3 (SAS Institute, Cary, NC), Stata Release 14 (StataCorp LLC, College Station, TX) and MPlus Version 7.4 (Muthén & Muthén, Los Angeles, CA).  
 Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
 All data will be inputted into a digital data collection system on a secure network  provided by  
[CONTACT_513120], REDCap.  The data system includes password protection and 
internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate A tablet computer will be used for data entry over secure Wi -Fi or 4gLTE data 
networks. There is no risk that if the iPad is lost that it will compromise study information. All data will be recorded on REDCap using secure data streaming with no local device storage. In addition, the iPad 
tablet devices used in this research will have security features that are designed to protect the device and 
data while enforcing strict network and platform security.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, OVERWRITE, OR  USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
 Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and maintained for recording data for each participant enrolled in the study. Data reported in the eCRF derived from source documents should be consistent with the source documents or the discrepancies should be explained 
and captured in a progress note and maintained in the participant’s official electronic study record.  
 
Hard copy data will be kept in a locked storage area in a locked office and building. Electronic data will be 
password- protected, stored only on a secure server, and backed up frequently. Only designated members 
of the study team will have access to Protected Health Information (PHI) and a variety of precautions will 
be taken to ensure the security of participant data.  
  
Study number:  i18-[ZIP_CODE]   Page 31 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  14.2 Study Records Retention  
Study documents will be retained for the longer of 3 years after close out or 5 years after final 
reporting/publication. These documents should be retained for a longer period, however, if required by 
[CONTACT_427]. No records will be destroyed without the written consent of the sponsor, if applicable. It 
is the responsibility of the sponsor to inform the investigator when these documents no longer need to be retained. 
 
14.3 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or MOP requirements. The 
noncompliance may be on the part of either the participant, the investigator, or the study site staff. 
Because of deviations, corrective actions are to be developed by [CONTACT_3483].  
 
These practices are consistent with ICH E6:  
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.[ADDRESS_664291] be reported to the local IRB per 
their guidelines. The site PI/study staff is responsible for knowing and adhering to their IRB requirements. 
Further details about the handling of protocol deviations will be included in the MOP.  
 
14.4 Publication and Data Sharing Policy  
This study will comply with the NIH Public Access Policy, which ensures that the public has access to the 
published results of NIH funded research. It requires scientists to submit final peer -reviewed journal 
manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for 
publication.  
 
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials regist ration policy as a condition for publication. The ICMJE defines a clinical trial as any research 
project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause- and-effect relationship between a medical intervention and a health outcome. 
Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process -of-care 
changes, and the like. Health outcomes include any biomedical or health- related measures obtained in 
patients or participants, including pharmacokinetic measures and adverse events. The ICMJE policy, and 
the Section [ADDRESS_664292] of 2007, requires that all clinical trials be registered in a public trials registry such  as ClinicalTrials.gov, which is sponsored by [CONTACT_118702]. Other biomedical journals are considering adopting similar policies. For interventional 
clinical trials performed under NIH IC grants and cooperative agreements, it is the grantee’s responsibility 
to register the trial in an acceptable registry, so the research results may be considered for publication in ICMJE member journals. The ICMJE does not review specific studies to determine whether registration is necessary; instead, the committee recommends that researchers who have questions about the need to register err on the side of registration or consult the editorial office of the journal in which they wish to 
publish.  
 
FDAAA mandates that a "responsible party" (i.e., the sponsor or designated principal investigator) register and report results of certain "applicable clinical trials":  
 
• Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I investigations of a product subject to FDA regulation;  
Study number:  i18-[ZIP_CODE]   Page 32 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  • Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation 
(other than small feasibility studies) and pediatric postmarket surveillance studies.  
• NIH grantees must take specific steps to ensure compliance with NIH implement ation of FDAAA.  
 
15 Study Finances  
15.1 Funding Source  
This study is financed through a grant from the US National Institutes of Health (NIH).  
15.[ADDRESS_664293] budgeted $17,100 for incentives for participating providers ($5,700 in Years 1, 2, 3). The incentives are intended to compensate for the supplemental time that  providers devote to each intervention 
participant appointment that is lost from regular clinical time. This will encourage providers to participate thoroughly in all elements of the intervention. The incentive will be $[ADDRESS_664294] budgeted $11, 850 for incentives for participating patients ($3,800 in Years 1, 2, 3). We anticipate 
enrolling approximately 228 participants by [CONTACT_513121] 3 to achieve adequate statistical power. The 
incentive will be a payment of  up to $6 5 per individual participant in cash to compensate patients for the 
coaching session.  A subset sample of individual participants (n=20- 30) will receive an incentive payment 
of $[ADDRESS_664295] with this study (patent ownership, royalties, or financial gain greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by [CONTACT_112393] a Committee- sanctioned conflict management plan that has 
been reviewed and approved by [CONTACT_513122] t his study.  All NYULMC  
investigators will follow the applicable  conflict of interest policies . 
Study number:  i18-[ZIP_CODE]   Page 33 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017   
  
Study number:  i18-[ZIP_CODE]   Page 34 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  18 References  
 
1. Draft Recommendation Statement: Prostate Cancer: Screening. 2017; 
https://www.uspreventiveservicestaskforce.org/Page/Document/draft -r ecommendation-
statement/prostate- cancer -screening1 , 2017.  
2. Myers RE, Daskalakis C, Cocroft J, et al. Preparing African- American men in community primary 
care practices to decide whether or not to have prostate cancer screening. Journal of the National Medical Association. 2005;97(8):1143- 1154.  
3. Myers RE, Daskalakis C, Kunkel EJ, et al. Mediated decision support in prostate cancer 
screening: a randomized controlled trial of decision counseling. Patient education and counseling. 
2011;83(2):240- 246. 
4. Belkora J, Edlow B, Aviv C, Sepucha K, Esserman L. Training community resource center and clinic personnel to prompt patients in listing questions for doctors: follow -up interviews about 
barriers and facilitators to the implementation of consultation planning. Implementation science : IS. 2008;3:6.  
5. Walter LC, Bertenthal D, Lindquist K, Konety BR. Psa screening among elderly men with limited 
life expectancies. Jama. 2006;296(19):2336- 2342.  
6. Stump TE, Dexter PR, Tierney WM, Wolinsky FD. Measuring patient satisfaction with physicians 
among older and diseased adults in a primary care municipal outpatient setting. An examination 
of three instruments. Medical care. 1995;33(9):958- 972. 
7. Sepucha K, Ozanne E, Silvia K, Partridge A, Mulley AG, Jr. An approach to measuring the quality 
of breast cancer decisions. Patient education and counseling. 2007;65(2):261- 269. 
8. Fenstermaker M, Hickman T, Gold H, et al. Abstract A15: How does doctor -patient 
communication about prostate cancer screening influence African- American patients' decisional 
conflict around screening decisions? Cancer Epi[INVESTIGATOR_9991] &amp; Prevention. 
2016;25(3 Supplement):A15- A15. 
9. Makarov DV, Chrouser K, Gore JL, et al. AUA White Paper on Implementation of Shared Decision Making into Urological Practice. Urology Practice. 2016;3(5):355- 363. 
10. Edwards A, Elwyn G, Hood K, et al. The development of COMRADE --a patient -based outcome 
measure to evaluate the effectiveness of risk communication and treatment decision making in 
consultations. Patient education and counseling. 2003;50(3):311- 322. 
11. Campbell C, Lockyer J, Laidlaw T, Macleod H. Assessment of a matched- pair instrument to 
examine doctor -patient communication skills in practising doctors. Medical education. 
2007;41(2):123- 129. 
12. Maly RC, Frank JC, Marshall GN, DiMatteo MR, Reuben DB. Perceived efficacy in patient -
physician interactions (PEPPI): validation of an instrument in older persons. Journal of the 
American Geriatrics Society. 1998;46(7):889- 894. 
13. Holmes -Rovner M, Kroll J, Schmitt N, et al. Patient satisfaction with health care decisions: the 
satisfaction with decision scale. Medical decision making : an international journal of the Society 
for Medical Decision Making. 1996;16(1):58- 64. 
14. Brehaut JC, O'Connor AM, Wood TJ, et al. Validation of a decision regret scale. Medical decision 
making : an international journal of the Society for Medical Decision Making. 2003;23(4):281- 292. 
15. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery  JC. Fostering 
implementation of health services research findings into practice: a consolidated framework for 
advancing implementation science. Implementation science : IS. 2009;4.  
16. Liu CF, Rubenstein LV, Kirchner JE, et al. Organizational cost of quality improvement for 
depression care. Health Serv Res. 2009;44(1):225- 244. 
17. Ma X, Wang R, Long JB, et al. The cost implications of prostate cancer screening in the Medicare population. Cancer. 2014;120(1):96- 102. 
18. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker -Corkery ES, Barry MJ. Natural 
experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325(7367):740.  
19. Mitchell JM. Urologists' sel f-referral for pathology of biopsy specimens linked to increased use 
and lower prostate cancer detection. Health affairs (Project Hope). 2012;31(4):741- 749. 
Study number:  i18-[ZIP_CODE]   Page 35 
Version: 1 0.01.20    
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as 
authorized in writing by [CONTACT_305120]: 5 MAY 2017  20. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data 
from SEER -Medicare. The Journal of urology. 2011;186(5):1830- 1834.  
21. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER -Medicare data. Medical care. 2002;40([ADDRESS_664296]):Iv -104-117. 
22.        Barry MJ, et al. (1992). American Urological Association symptom index for benign prostatic 
hyperplasia. Journal of Urology, 148(5): 1549 –1557.  
23. Davis TC, Long SW, Jackson RH, et al. Rapid estimate of adult literacy in medicine: a shortened screening instrument. Family Medicine. 1993;25(6):391- 395. 
24. Fagerlin A, Zikmund- Fisher BJ, Ubel PA, Jankovic A, Derry HA, Smith DM. Measuring numeracy 
without a math test: Development of the subjective numeracy scale. Medical Decision Making. 
2007;27(5):672- 680. 
25. Zikmund- Fisher BJ, Smith DM, Ubel PA, Fagerlin A. Validation of the subjective numeracy scale 
(SNS): Effects of low numeracy on comprehension of risk communications and utility elicitations. Medical Decision Making. 2007;27(5):663- 671. 
[ADDRESS_664297] in Physician scale: a measure to assess interpersonal trust in patient -physician relationships. Psychological Reports . 1990;67(3):1091-
1100.  
27. Rose A, Peters N, Shea JA, Armstrong K. Development and testing of the health care system distrust scale. J Gen Intern Med. 2004;19(1):57 –63.  
28. Degner L., Sloan J., & Venkatesh P. The Control Preferences Scale. Canadian Journal of Nursing 
Research Archive.  1997;29 (3):21- 43. 
29.  Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect . 
2001;4(2):99– 108.  
30. Watson  E, Hewitson P , Brett J , Bukach C , Evans E, Edwards A, Elwyn  G, Cargill  A, Austoker J. 
Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: A randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. Patient Education and Counseling. 
2006;63(3 ):367-379 
31. O'Connor A. Decision Self -Efficacy Scale. 1995.  
32. O'Connor AM. Validation of a decisional conflict scale. Medical Decision Making. 1995;15(1):25-
30. 
33. Aarons GA. Mental health provider attitudes toward adoption of evidence- based practice: The 
Eviden ce-Based Practice Attitude Scale (EBPAS). Mental health services research. 2004;6(2):61-
74. 
34. Shore BE, Franks P. Physician satisfaction with patient encounters: Reliability and validity of an encounter -specific questionnaire. Medical care. 1986;24(7):580- 589. 
35. Bertram DA, Opi[INVESTIGATOR_513094], Brown JL, et al. Measuring physician mental workload: reliability and 
validity assessment of a brief instrument. Medical care. 1992;30(2):95- 104. 
 
 
19 Attachments  
These documents are relevant to the protocol, but they are not considered part of the protocol.  They are stored and modified separately. As such, modifications to these documents do not require protocol amendments.  
 
Study number:  i18-[ZIP_CODE]                                                                               page 1  Version: 1 0.01.20  
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center.  Do not disclose or use except as authorized in writing by [CONTACT_248710]/Device Template Version: 13 JUN 2016  
Attachment  A 
Schedule  
 
   
 
     
 
     
 
    
 
     
 
     
 
    
 
Study number:  i18-[ZIP_CODE]   Page 2 
Version: [ADDRESS_664298] udy sponsor  
Behavioral Intervention Template Version: [ADDRESS_664299] scale82  X X X 
 Satisfaction with Decision Scale83   X X 
 Decisional Regret84    X 
Hypothesis 1.3      
 Screening choice (Epic Query)    X X 
Study number:  i18-[ZIP_CODE]   Page 3 
Version: [ADDRESS_664300] udy sponsor  
Behavioral Intervention Template Version: 5 MAY 2017   
 
 
   Table 2 – Quantitative Provider Measures  
Measure  Initiation  Post encounter  Completion  
Demographics and 
Preferences     
 Demographics  X   
 Preference for EBM76 X  X 
Specific Aim 2     
Hypothesis 2.1     
 Satisfaction85  X  
 Difficulty86  X  
 Communication75  X  